ALADDIN Study: Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation
|ClinicalTrials.gov Identifier: NCT00063310|
Recruitment Status : Completed
First Posted : June 26, 2003
Last Update Posted : December 11, 2009
Voyager Pharmaceutical Corporation
Information provided by:
National Institute on Aging (NIA)
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Completed|
|Actual Primary Completion Date :||February 2006|
|Actual Study Completion Date :||February 2006|
Smith MA, Perry G, Atwood CS, Bowen RL. Estrogen replacement and risk of Alzheimer disease. JAMA. 2003 Mar 5;289(9):1100; author reply 1101-2.
Bowen RL, Smith MA, Harris PL, Kubat Z, Martins RN, Castellani RJ, Perry G, Atwood CS. Elevated luteinizing hormone expression colocalizes with neurons vulnerable to Alzheimer's disease pathology. J Neurosci Res. 2002 Nov 1;70(3):514-8.